Latest News and Press Releases

Dewpoint's DPTX3186 receives FDA Orphan Drug Designation for gastric cancer - the first ever granted to a condensate-modulating therapeutic.

Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for DPTX3186.

Dewpoint Therapeutics will present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting in Boston

Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer.Strong support from leading investors and global pharma partners continues to...

Dewpoint will present two posters at AACRCondensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancerC-mods modulate the oncogenic function of historically...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of action for the treatment of Wnt-driven cancersDPTX3496...

BOSTON and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s...

- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients - Mitsubishi...

Orally administered small molecule condensate modulators (c-mods) are a novel class of therapeutic agents designed to target condensates to modify diseaseDPTX3186 is Dewpoint’s first development...

Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutationsPost-licensing,...